GlassScriptPhysician profile
Richard G Clark
NPI 1962406793
$3,951.04
in general payments reported to CMS, 2019-2025
30 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $424 · 2021: $1,018 · 2022: $1,246 · 2023: $618 · 2024: $256 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,086.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $825.30 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $436.44 | 2021-2025 | Ubrelvy, Vraylar |
| Amgen INC. | $334.87 | 2020-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.17 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $305.18 | 2019-2025 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $190.05 | 2022-2025 | |
| Lilly USA, LLC | $187.64 | 2019-2024 | Mounjaro |
| Pfizer INC. | $168.15 | 2020-2024 | |
| Evoke Pharma, INC. | $163.59 | 2022-2023 | Gimoti |
| Glaxosmithkline, LLC. | $152.78 | 2019-2023 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $152.72 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $140.72 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $117.69 | 2022 | |
| Collegium Pharmaceutical, INC. | $74.48 | 2021-2023 | Xtampza |
| Novartis Pharmaceuticals Corporation | $62.77 | 2019-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $42.06 | 2020 | |
| Allergan, INC. | $35.86 | 2020 | |
| Exact Sciences Corporation | $33.14 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.46 | 2025 | Caplyta |
| Pacira Therapeutics, INC. | $21.90 | 2021 | |
| Scilex Pharmaceuticals INC. | $21.12 | 2019 | |
| Philips North America LLC | $19.52 | 2024 | (Ck7) Extended Holter |
| Lundbeck LLC | $19.12 | 2023 | Rexulti |
| Corcept Therapeutics | $19.00 | 2023 | Korlym |
| Acadia Pharmaceuticals INC | $17.33 | 2023 | Daybue |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.41 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.62 | 2023 | Nuzyra |
| Sunovion Pharmaceuticals INC. | $15.56 | 2019 | |
| Astellas Pharma US INC | $12.07 | 2020 | |
| Ironwood Pharmaceuticals, INC | $11.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.